What medical indications are treated with Ruxolitinib topical?

Ruxolitinib topical (Drugs Affecting The Immune Response) is a pharmaceutical active substance. It is indicated for the treatment of Atopic Dermatitis, Vitiligo.

What is the recommended dosage for Ruxolitinib topical?

Standard adult dosage: Cream – Thin layer (twice daily). Pediatric dosage: Cream – thin layer. Always consult a registered physician for individualized dosage adjustments based on clinical assessment.

Is Ruxolitinib topical safe during pregnancy and breastfeeding?

Ruxolitinib topical is classified under Pregnancy Category "Not Assigned". Always consult your healthcare provider or OB/GYN before taking this medication during pregnancy or lactation.

What are the common side effects of Ruxolitinib topical?

**1-10%:**; Nasopharyngitis (3%); Bronchitis (1%); Ear infection (1%); Eosinophil count increased (1%); Urticaria (1%); Diarrhea (1%); Folliculitis (1%); Tonsillitis (1%); Rhinorrhea (1%); **Less than 1%:**; Neutropenia;

Dose.bd

Medicine Overview

Indication Guideline Dose Administration Side Effect Interaction Pregnancy Lactation Special Use Precaution Overdose Pharmacology Storage

Indication

Know Medicine, Follow Guideline

Details coming soon

Adult Dose

Clinical Information	Administration Information
Indication: Atopic Dermatitis Age: Adults Condition: Mild-to-moderate, nonimmunocompromised, disease not adequately controlled with topical prescription therapies or when those therapies are not advisable	Dose: Cream – Thin layer Frequency: twice daily Note: Apply to affected areas of up to 20% body surface area; not to exceed greater than 60 grams/week or one 100-gram tube/2 weeks. If signs and symptoms do not improve within 8 weeks, re-examine the patient.
Indication: Vitiligo Age: Adults Condition: Nonsegmental	Dose: Cream – Thin layer Frequency: twice daily Duration: greater than 24 weeks Note: Apply to affected areas of up to 10% body surface area; not to exceed greater than 60 grams/week or one 100-gram tube/2 weeks. Satisfactory patient response may require treatment for greater than 24 weeks. If no meaningful repigmentation is observed by 24 weeks, re-evaluate the patient.

Child Dose

Clinical Information	Administration Information
Indication: Atopic Dermatitis Age: less than 12 years	Dose: Cream – thin layer Note: Safety and efficacy not established
Indication: Atopic Dermatitis Age: greater than or equal to 12 years	Dose: Cream – thin layer Frequency: twice daily Note: Apply to affected areas of up to 20% body surface area; not to exceed greater than 60 g/week or one 100-gram tube/2 weeks. Stop using when signs and symptoms (eg, itch, rash, redness) resolve. If signs and symptoms do not improve within 8 weeks, re-examine the patient.

Administration

Apply a thin layer of ruxolitinib topical cream twice daily to affected skin areas, ensuring the total body surface area treated does not exceed 20 percent for atopic dermatitis or 10 percent for non-segmental vitiligo. This medication is for cutaneous use only and must not be applied to ophthalmic, oral, or intravaginal mucosa. Patients should wash their hands after application unless the hands are the treatment site, and treated skin should not be washed for at least two hours. For atopic dermatitis, use is restricted to patients 2 years and older, with a maximum weekly dose of 60 grams for those 12 and older or 60 grams every two weeks for children aged 2 to 11. In non-segmental vitiligo, it is indicated for patients 12 years and older with a maximum of 60 grams per week. Do not use with occlusive dressings or in combination with therapeutic biologics or other JAK inhibitors. Treatment should be discontinued if atopic dermatitis symptoms do not improve within 8 weeks or if vitiligo repigmentation is not meaningful by 24 to 52 weeks.

Side Effect

1-10%:

Less than 1%:

Drug Interaction

Details coming soon

Disease Interaction

Details coming soon

Pregnancy

US FDA Note

BNF Recommendation Note

AU TGA Note

Lactation

US FDA Note

BNF Recommendation Note

AU TGA Note

Special Use

Renal Impairment Note

Hepatic Impairment Note

Pediatric & Geriatric Use Note

Precaution

Serious Infections

Thrombocytopenia, Anemia, and Neutropenia

Overdose

Pharmacology

Mechanism of Action

Pharmacokinetics

Pharmacodynamics

Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.